Type 1 diabetes (T1D) is an autoimmune disease that results from a complex interplay of genetics and environmental factors, leading to a dysregulated immune system and loss of peripheral and central tolerance. The DIL studies the aetiology of T1D, aiming to identify disease-associated molecules and pathways that could be targeted for therapeutic intervention. We are currently investigating immunotherapy with interleukin-2 to rebalance the immune system and restore Treg-mediated tolerance. I am investigating the immunotherapeutic potential of IL-2, attempting to specifically increase the number and function of Tregs both in humans and preclinical animal models, and investigating biomarkers of activity of IL-2 treatment.
